Injunction Stops Sales Of Qiagen GeneReader
Executive Summary
The system was launched late last year, but a preliminary injunction issued by a federal court in California will now block Qiagen from marketing its GeneReader sequencing system in the US. Illumina had filed a patent claim against the system, and the court found that the claim is likely to succeed.
You may also be interested in...
Qiagen Moves Into Next-Gen Sequencing
Qiagen has acquired privately held Intelligent Bio-Systems, a developer of next-generation sequencing (NGS) instruments aimed at the clinical research market. IBS’ technology, along with a newly expanded collaboration with bioinformatics provider SAP, is the cornerstone of a new NGS initiative at Qiagen.
Medtronic Recalls Cardiac Defibrillators Due To Reduced Shock Potential
The device giant is recalling Cobalt and Crome defibrillators because they may deliver weaker shocks than intended.
US FDA Waits Until December To Enforce Unique Device Identifier Database For Low-Risk Devices
Agency won’t require manufacturers to submit class I devices to the database for an extra 75 days, and doesn't plan to enforce GUDID regulations against consumer health products.